| Literature DB >> 27923387 |
Serghei Malkov1, John A Shepherd2, Christopher G Scott3, Rulla M Tamimi4, Lin Ma5, Kimberly A Bertrand6, Fergus Couch3, Matthew R Jensen3, Amir P Mahmoudzadeh2, Bo Fan2, Aaron Norman3, Kathleen R Brandt3, V Shane Pankratz3, Celine M Vachon3, Karla Kerlikowske5.
Abstract
BACKGROUND: Several studies have shown that mammographic texture features are associated with breast cancer risk independent of the contribution of breast density. Thus, texture features may provide novel information for risk stratification. We examined the association of a set of established texture features with breast cancer risk by tumor type and estrogen receptor (ER) status, accounting for breast density.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27923387 PMCID: PMC5139106 DOI: 10.1186/s13058-016-0778-1
Source DB: PubMed Journal: Breast Cancer Res ISSN: 1465-5411 Impact factor: 6.466
Image texture features that are currently defined for all study participants
| Analysis groups | Texture features | Texture feature name | References |
|---|---|---|---|
| Gray-level histogram | Standard deviation | STD | [ |
| Skewness | Skewness | ||
| Kurtosis | Kurtosis | ||
| Balance | Balance | ||
| Gray-level co-occurrence matrix (GLCM) | GLCM Energy | Energy | [ |
| GLCM Entropy | Entropy | ||
| GLCM Dissimilarity | Dissimilarity | ||
| GLCM Contrast | Contrast | ||
| GLCM Homogeneity | Homogeneity | ||
| GLCM Correlation | Correlation | ||
| GLCM Mean | GLCM Mean | ||
| GLCM Variance | GLCM Variance | ||
| Neighborhood gray-tone difference matrix (NGTDM) | NGTDM Coarseness | NGTDM Coarseness | [ |
| NGTDM Contrast | NGTDM Contrast | ||
| NGTDM Complexity | Complexity | ||
| NGTDM Strength | Strength | ||
| NGTDM Busyness | Busyness | ||
| Edge frequency analysis | Mean gradient | Mean_Gradient | [ |
| Fourier transform (FT) analysis, power spectrum | RMS (root mean square) | FT_RMS | [ |
| FMP (first moment of power spectrum) | FT_FMP | ||
| SMP (second moment of power spectrum) | FT_SMP | ||
| FD (fractal dimension) from power spectrum exponent | FT_FD | ||
| Fractal analysis | Intercept of the plot of the standard deviation of the high frequency image as a function of the size the kernel | CD_Yint | [ |
| Continuous dimension (CD), slope and intercept | CD_Slope | ||
| HZ_PROJ | HZ_PROJ | ||
| FD of the standard deviation | FD_Sigma | ||
| FD of image using thresholds from 5%-85% | FD_TH_5: FD_TH_85 | ||
| FD of the surface of the breast considering the gray value representing the height | FD_CALDWELL | ||
| FD, Minkowski method | FD_Minkowski |
Baseline characteristics of study population matched by age, date of mammogram, and study
| Cases | Controls | |
|---|---|---|
|
| 1171 | 1659 |
| Mean age at mammogram (years) | 55.4 (10.6) | 55.3 (10.6) |
| Mean age at diagnosis (years) | 60.5 (10.8) | – |
| Mean BMI (kg/m2) | 25.7 (6.1) | 25.8 (6.8) |
| Body mass index categories (kg/m2)* | ||
| < 25 | 551 (47.1%) | 854 (51.5%) |
| 25–29 | 369 (31.5%) | 443 (26.7%) |
| 30–34 | 155 (13.2%) | 196 (11.8%) |
| 35+ | 73 (6.2%) | 136 (8.2%) |
| Unknown | 23 (2.0%) | 30 (1.8%) |
| Menopausal Status | ||
| Premenopausal | 430 (36.7%) | 632 (38.1%) |
| Postmenopausal | 697 (59.5%) | 962 (58%) |
| Unknown | 44 (3.8%) | 65 (3.9%) |
| Parity | ||
| Nulliparous | 169 (14.4%) | 218 (13.1%) |
| Parous | 977 (83.4%) | 1415 (85.3%) |
| Unknown | 25 (2.1%) | 26 (1.6%) |
| Postmenopausal hormone therapya* | ||
| Not current | 255 (51.5%) | 367 (57.5%) |
| Current, estrogen | 116 (23.4%) | 156 (24.5%) |
| Current, estrogen + progestin | 124 (25.1%) | 115 (18.0%) |
| Family history* | ||
| No | 973 (83.1%) | 1453 (87.6%) |
| Yes | 196 (16.7%) | 206 (12.4%) |
| Unknown | 2 (0.2%) | 0 (0%) |
| Standardized mean percent mammographic density (%)* | 32.9 (18.7) | 27.9 (18.4) |
| Standardized mean dense area (cm2)* | 63.5 (43.1) | 52.2 (37.8) |
| Standardized mean non-dense area (cm2)* | 149.4 (98.7) | 158.9 (102.1) |
Data are presented as the mean (standard deviation) or number (%).
aAmong postmenopausal women in MMHS, NHS, NHSII, and SFMR
*p < 0.05, cases versus controls
BMI body mass index
The top 15 of 46 analyzed features were significant (p < 0.05) in the case–control models
| Feature | All five studies OR (95% CI) |
| AUCa | MMHS OR (95% CI) | MCMAM OR (95% CI) | SFMR OR (95% CI) | NHS OR (95% CI) | NHSII OR (95% CI) |
|---|---|---|---|---|---|---|---|---|
|
| 1171/1659 | 62/112 | 242/395 | 104/206 | 412/454 | 351/492 | ||
|
|
|
| 0.621 |
|
|
|
|
|
|
| 0.88 (0.81–0.96) | 0.003 | 0.621 | 1.03 (0.71–1.51) | 0.84 (0.70–1.01) | 1.35 (0.97–1.89) | 0.85 (0.73–0.98)* | 0.86 (0.73–1.00) |
|
|
|
| 0.620 |
|
|
|
|
|
|
|
|
| 0.621 |
|
|
|
|
|
|
| 0.89 (0.82–0.98) | 0.012 | 0.620 | 0.86 (0.56–1.31) | 0.88 (0.70–1.12) | 1.17 (0.84–1.64) | 0.90 (0.77–1.06) | 0.87 (0.75–1.01) |
|
| 1.11 (1.02–1.20) | 0.015 | 0.620 | 1.43 (1.00–2.06) | 1.11 (0.92–1.34) | 1.07 (0.80–1.42) | 1.03 (0.89–1.19) | 1.15 (0.98–1.34) |
|
| 0.89 (0.81–0.98) | 0.015 | 0.620 | 0.91 (0.61–1.34) | 0.85 (0.69–1.06) | 0.84 (0.60–1.16) | 0.86 (0.74–1.01) | 0.95 (0.80–1.12) |
|
| 0.88 (0.80–0.98) | 0.016 | 0.620 | 0.95 (0.57–1.58) | 0.78 (0.59–1.04) | 1.50 (0.98–2.29) | 0.97 (0.82–1.15) | 0.81 (0.68–0.96)* |
|
| 0.88 (0.79–0.98) | 0.017 | 0.621 | 0.65 (0.34–1.24) | 0.85 (0.67–1.09) | 1.07 (0.72–1.59) | 0.84 (0.70–1.00)* | 0.91 (0.74–1.13) |
|
| 1.10 (1.02–1.20) | 0.019 | 0.619 | 1.43 (0.97–2.13) | 1.17 (0.97–1.41) | 1.00 (0.74–1.35) | 0.99 (0.86–1.15) | 1.18 (1.02–1.38)* |
|
| 1.10 (1.01–1.20) | 0.023 | 0.620 | 1.43 (0.95–2.14) | 0.92 (0.76–1.13) | 1.38 (1.00–1.90) | 1.09 (0.94–1.26) | 1.18 (1.01–1.37)* |
|
| 0.91 (0.83–0.99) | 0.033 | 0.620 | 0.72 (0.48–1.09) | 1.10 (0.90–1.34) | 0.74 (0.53–1.03) | 0.92 (0.79–1.06) | 0.85 (0.73–0.99)* |
|
|
|
| 0.620 |
|
|
|
|
|
|
| 0.92 (0.84–1.00) | 0.046 | 0.619 | 0.98 (0.65–1.46) | 0.89 (0.71–1.11) | 1.12 (0.82–1.53) | 0.93 (0.79–1.08) | 0.90 (0.78–1.05) |
|
| 1.09 (1.00–1.18) | 0.048 | 0.619 | 1.42 (0.96–2.11) | 1.09 (0.91–1.31) | 1.04 (0.79–1.39) | 0.96 (0.83–1.11) | 1.21 (1.04–1.42)* |
Features listed in italics were significant in at least two studies.
Results are presented as odds ratio (OR) and 95% confidence interval (CI) per 1 standard deviation in normalized feature after adjustment for age, body mass index (BMI), family history, percent density (PD), and study.
aAdjusted for age, BMI, family history, PD, and study. Area under the curve (AUC) for the adjustment factors only is 0.617 (95% CI 0.596–0.638)
*Study p values < 0.05.
Fig. 1Dendrogram of cluster analysis of the top 15 features with PD, age, and BMI. Similar features cluster together. Percent density groups closely with body mass index (BMI) and age. The figure is restricted to the controls
Pearson correlation coefficient for the top 15 significant features
Correlations calculated using control subjects. Gray and gray with line patterns highlight the strength of positive and negative associations, respectively
Fig. 2Representative images with similar densities but different groups: FD_TH_75 values in the top and bottom 20% of values matched by BMI, PD, age, case status, and study. The top row has similar low PD densities (17%) while the bottom row has a relatively high PD (67%). The inner black delineation lines in each breast image show the delineation lines of the tissue used to describe FD_TH_75. The outer black delineation lines show the delineation lines of the tissue used to describe FD_TH_15. The top left and bottom left images show a top 20th percent tile value of FD_TH_75 while the top right and bottom right images show a bottom 20th percent tile value
Risk associated of either DCIS or invasive cancer for each feature
| Feature | DCIS | Invasive | ER– | ER+ | ||||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) |
|
| OR (95% CI) | OR (95% CI) |
|
| |
|
| 254/1659 | 908/1659 | 116/1291 | 746/1291 | ||||
| FD_TH_75 | 0.87 (0.74–1.01) | 0.87 (0.78–0.96) | 0.010 | 0.98 | 0.84 (0.67–1.06) | 0.88 (0.79–0.99) | 0.048 | 0.72 |
| Energy | 0.88 (0.76–1.02) | 0.88 (0.80–0.96) | 0.011 | 0.93 | 0.85 (0.69–1.05) | 0.86 (0.78–0.95) | 0.009 | 0.90 |
| Entropy | 1.18 (1.02–1.38) | 1.13 (1.03–1.25) | 0.010 | 0.60 | 1.16 (0.93–1.44) | 1.15 (1.03–1.28) | 0.024 | 0.96 |
| FD_TH_70 | 0.85 (0.72–1.00) | 0.87 (0.79–0.97) | 0.015 | 0.75 | 0.84 (0.67–1.06) | 0.89 (0.79–1.00) | 0.085 | 0.64 |
| FD_TH_80 | 0.90 (0.77–1.04) | 0.89 (0.81–0.98) | 0.034 | 0.90 | 0.85 (0.68–1.05) | 0.89 (0.80–1.00) | 0.066 | 0.64 |
| FD_TH_10 | 1.19 (1.04–1.38) | 1.09 (0.99–1.19) | 0.022 | 0.21 | 1.03 (0.84–1.26) | 1.06 (0.96–1.18) | 0.479 | 0.75 |
| Kurtosis | 0.86 (0.73–1.00) | 0.90 (0.81–0.99) | 0.032 | 0.58 | 0.98 (0.78–1.22) | 0.91 (0.81–1.01) | 0.216 | 0.53 |
| FD_TH_65 | 0.84 (0.71–0.99) | 0.89 (0.80–0.99) | 0.035 | 0.49 | 0.83 (0.65–1.06) | 0.91 (0.81–1.03) | 0.170 | 0.46 |
| FD_Minkowski | 0.90 (0.74–1.08) | 0.86 (0.77–0.97) | 0.042 | 0.71 | 0.77 (0.59–1.01) | 0.89 (0.78–1.01) | 0.063 | 0.32 |
| Busyness | 1.15 (1.00 –1.33) | 1.09 (1.00–1.19) | 0.053 | 0.46 | 0.92 (0.75–1.14) | 1.09 (0.99–1.21) | 0.128 | 0.12 |
| Homogeneity | 1.05 (0.90–1.22) | 1.13 (1.03–1.24) | 0.042 | 0.36 | 1.06 (0.86–1.31) | 1.12 (1.01–1.24) | 0.091 | 0.62 |
| Dissimilarity | 0.96 (0.83–1.12) | 0.89 (0.81–0.98) | 0.057 | 0.35 | 0.95 (0.77–1.17) | 0.89 (0.81–0.99) | 0.110 | 0.61 |
| FD_TH_60 | 0.85 (0.71–1.02) | 0.9 (0.8–1.01) | 0.077 | 0.56 | 0.9 (0.69–1.15) | 0.92 (0.81–1.04) | 0.348 | 0.85 |
| FD_TH_85 | 0.92 (0.79–1.06) | 0.91 (0.83–1) | 0.130 | 0.98 | 0.89 (0.72–1.09) | 0.91 (0.82–1.01) | 0.173 | 0.77 |
| FD_TH_15 | 1.2 (1.04–1.39) | 1.06 (0.97–1.16) | 0.034 | 0.09 | 0.96 (0.78–1.18) | 1.05 (0.95–1.16) | 0.572 | 0.43 |
Results are presented as odds ratio (OR) and 95% confidence interval (CI) per 1 standard deviation in normalized feature after adjustment for age, family history, percent density, and study
*p value refers to two degrees of freedom to test for evidence of association with ductal carcinoma in situ (DCIS) or invasive cancer
**Heterogeneity p value (p het) to test for differences in effect between tumor subgroups
ER estrogen receptor